What it is
Amycretin is a single lab-made molecule that acts on two kinds of receptor: the GLP-1 receptor and the amylin receptor12. GLP-1 is a hormone your gut releases when you eat11, and amylin is a hormone from the pancreas that brings on a feeling of fullness12. Drugs that act on each of these receptors have led to weight loss and lower blood sugar in trials1. Papers published in 2026 describe a third target as well, the receptor for calcitonin34. Calcitonin is a hormone made by the thyroid gland9. Amycretin is being developed in two forms, a weekly injection under the skin and a daily pill34. Newer papers and trial records call it zenagamtide36.
What makes it distinct
Amycretin acts on GLP-1 and amylin receptors with one molecule, rather than by pairing two drugs12.
What the evidence shows
The first published trials were in adults with overweight or obesity, at a single US research centre12. One tested the pill for up to 12 weeks (phase 1)1. Another tested the weekly injection for up to 36 weeks (phase 1b/2a)2. In the injection study, people on amycretin lost more weight than people on placebo (a dummy injection)2. In both, stomach and gut side effects were the most common, and most were mild to moderate12. A large number of participants withdrew from the injection study, and a high proportion of them left for reasons unrelated to side effects2. A phase 2 trial in adults with type 2 diabetes tested both the weekly injection and the daily pill for 36 weeks, and its results were published as two papers3410. For both forms, HbA1c, a blood test for average blood sugar over the past few months, fell more than on placebo at every dose tested34. Phase 3 trials, called AMAZE, began in 202656.
Open questions
- Results of the phase 3 AMAZE trials. AMAZE 1, testing the weekly injection in adults with obesity, began in February 2026 and is still recruiting5.
- Long-term safety and effects. The longest published trials ran 36 weeks234.
- What the calcitonin receptor adds on its own. The 2026 papers name it as a target, and their published summaries don't report what it adds by itself34.
Worth knowing
Products labelled zenagamtide are sold online, and some websites say they're selling it 'for research purposes only' or 'not for human use'7. Tidepath records what you tell it you're taking. It can't check what's in a vial.
Sources
- Gasiorek A et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. Lancet 2025;406:135-148. PMID 40550229
- Dahl K et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet 2025;406:149-162. PMID 40550231
- Mora P et al. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: phase 2 trial. Lancet 2026;408:621-635. PMID 42532080
- Mora P et al. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: phase 2 trial. Lancet 2026;408:607-620. PMID 42532079
- ClinicalTrials.gov NCT07339423: AMAZE 1, Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Obesity
- ClinicalTrials.gov NCT07720271: AMAZE 9, Efficacy and Safety of Once-daily Oral Zenagamtide in Participants With Obesity
- Rubin R. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. JAMA, published online 9 October 2026 (Medical News). PMID 42853576
- FDA: Novel Drug Approvals for 2026 (content current as of 10/20/2026)
- MIACALCIN (calcitonin salmon) injection, FDA prescribing information (DailyMed, Mylan Institutional, revised 9/2024)
- ClinicalTrials.gov NCT06542874: Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018 (PubMed 29617641)
- Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160-2172. PMID 34798060
More in Amylin drugs